- Reaction score
- 615
It’s pretty safe to assume that Replicel is in dire need of some capital - take a look at their share price over the last few years. If they had results of Shiseido’s RCH phase 2 trial, they would have released them by now. The only time their share price has jumped exponentially has been when good news regarding RCH 01 has surfaced.
This leads me to believe that Replicel do not possess the Phase 2 results and that they are in conflict with Shiseido over them.
https://www.streetinsider.com/dr/news.php?id=15849637&gfv=1
Yep it's more than a safe assumption. They've burned through all of the Shiseido and YOFOTO money already and had to issue more stocks last week just to be able to pay its directors. Genuinely don't have the capital to continue through next year so something has to give.
